By Colin Kellaher
Bluebird bio is shedding about a quarter of its workforce as part of a restructuring plan aimed at reducing its cash operating expenses by around 20% and enabling quarterly cash flow break-even in the second half of 2025.
Bluebird on Tuesday said it will further sharpen its focus on the commercial launches of its Lyfgenia, Zynteglo and Skysona gene therapies as it looks to attract the additional capital needed to extend its cash runway.
The Somerville, Mass., company, which has about 375 employees according to data from FactSet, said it will incur charges of about $3.7 million in cash expenditures for severance and employee termination-related costs.
Bluebird said its cash flow break-even target assumes scaling to about 40 drug product deliveries per quarter. The company said there have been 41 patient starts across its portfolio so far this year, and that it expects about 40 patient starts in the fourth quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 24, 2024 07:26 ET (11:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。